section name header

Evidence summaries

ACE Inhibitors and other Antihypertensive Drugs in Patients with Type 2 Diabetes

ACE inhibitors reduce the risk of myocardial infarction, cardiovascular events and all-cause mortality in hypertensive patients with type 2 diabetes. Level of evidence: "A"

A systematic review 1 including 4 RCTs with a total of 2 180 subjects was abstracted in DARE. The analysis showed a statistically-significant benefit of ACE inhibitors on the outcome of acute myocardial infarction, compared with alternative treatments there was a 63% reduction (P <0.001) and the RR was 0.37 (95% CI: 0.24 to 0.57). On the outcome of cardiovascular events, compared with alternative treatments there was a 51% reduction and the RR was 0.49 (95% CI: 0.36 to 0.67). Also, there was a benefit of ACE inhibitors on the outcome of all-cause mortality, compared with alternative treatments there was a 62% reduction (P=0.010) and the RR was 0.57 (95% CI: 0.38 to 0.87). ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials, RR 0.76 (95% CI: 0.48 to 1.22).

The following decision support rules contain links to this evidence summary:

    References

    • Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000 Jul;23(7):888-92. [PubMed] [DARE]

Primary/Secondary Keywords